The largest community of pharma leaders

Otsuka, Janssen & IQVIA discuss how collect deeper patient insights for stronger patient outcomes

Dear Colleague

Patient insights are crucial. They are the key to the creation of successful, targeted programmes and new service offerings. They dictate the delivery of successful outcomes. But if we’re to gain deeper, richer insights, we must construct frameworks that help more patients articulate their value-drivers and hit on critical touchpoints.
At eyeforpharma, they’ve brought global leaders from Otsuka, Janssen, IQVIA & patient advocate Teresa Ferreiro together for a webinar on how to gather deeper patient insights that lead to targeted, personalised services, and ultimately, stronger patient outcomes.
  • Why designing frameworks with the patient in mind is insufficient: Work with patients from the beginning to ensure you collect comprehensive and pertinent insights
  • How to build your business case: Use insights to outline the commercial imperative of new services
  • It’s not just patients: When and how to engage HCPs and carers to gather a holistic view on how programmes can best operate
Join eyeforpharma on November 6 at 2pm London / 3pm Paris / 9am NY. Sign up for free here.
If you can’t make it, still sign-up and you’ll get the recording automatically to your inbox afterwards.
If you have any questions about this webinar, please contact Matt Atkinson, Head of Patient Initiatives, at eyeforpharma on matkinson@eyeforpharma.com.
I hope you find these useful!
 
Best regards,
Lucy Muñiz MD
Editor The Pharmaceutical Marketing Group
http://magazine.pharmamkt.net 

Recent Articles

Reven Pharmaceuticals Reports on the Importance of Micronutrients and Vitamins for COVID-19 in a Prestigious Medical Journal

GOLDEN, Colo.--(BUSINESS WIRE)--Reven Holdings, Inc. (“Reven”), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment...

Anthony Welters Joins Gilead Sciences’ Board of Directors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Anthony Welters has been appointed to the company’s Board of Directors. Mr. Welters retired...

AVIA Names Linda Finkel as CEO

CHICAGO--(BUSINESS WIRE)--AVIA, the nation’s leading digital transformation partner for healthcare organizations, announced that its board of directors has appointed AVIA President Linda Finkel to...

Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced...

U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury®...